drugset / Trial / NCT07279584

Golidocitinib Combined With GemOx in RR PTCL

NCT07279584

Phase 2 Not yet recruiting 31 enrolled Ruijin Hospital
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of golidocitinib in combination with the GemOx regimen in r/r PTCL

Timeline

Start
2025-12-20
Primary completion
2026-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Golidocitinib Small molecule 150 mg Oral
Background Gemcitabine Small molecule 1000 mg/m2
Background Oxaliplatin Small molecule 100 mg/m2